BofA reiterates Buy on Texas Instruments stock, cites broad recovery By Investing.com

BofA Securities reiterated a Buy rating and $320 price target on Texas Instruments after first-quarter results and second-quarter guidance, citing a broader and higher-quality recovery. The company reported industrial growth of 30% year over year and 20% quarter over quarter, with no evidence of customer pull-in and management cautiously optimistic on second-half demand. Several other analysts also raised targets, reinforcing a positive read-through for TXN, which has already climbed 22.8% in the past week to $277.14.

Analysis

TXN is functioning as a read-through on the industrial semiconductor cycle, but the more important signal is that the recovery is being led by channels with higher inventory discipline and less consumer cyclicality. That usually benefits the most asset-light analog names with direct customer relationships and short design-win cycles, while more exposed discrete/auto-semicap vendors can lag if the rebound is broad but not deep enough to force aggressive restocking. If this is a real inflection rather than a one-quarter air pocket, the second-order winner is likely capex sentiment across U.S. industrial automation and factory-control names, because TI’s commentary implies OEM ordering is normalizing without panic buying.

The risk is that the move has already priced in a lot of the good news: after a sharp weekly rerate, the stock is now trading more like a late-cycle quality compounder than a cyclical recovery name. The key catalyst window is the next 4-8 weeks, when second-quarter order cadence will either validate durability or expose that the rebound is still “one quarter at a time.” If bookings flatten while inventory days remain elevated in adjacent supply chains, the market can quickly de-rate even if reported numbers stay decent.

The consensus may be underestimating how much of the upside is already in the name versus peers. A better expression may be relative value rather than outright long: TXN can keep outperforming if the industrial rebound broadens, but its risk/reward is now less attractive than lower-expectation analogs where incremental evidence can still re-rate multiples. The most likely mistake is extrapolating one strong quarter into a full-cycle upturn before the lead-time and customer-confidence data have confirmed it.

Key Decisions for Investors

• Trim TXN into strength over the next 1-2 weeks; upside from here looks more like a grind than a rerate, while any disappointment in Q2 cadence could mean a 10-15% retracement.
• Pair long TXN / short a weaker-quality industrial semis basket for 1-2 quarter horizon; the thesis is quality-plus-U.S.-manufacturing exposure should outperform if the rebound is real, but the short leg should be in names with more inventory sensitivity and weaker balance sheets.
• Buy TXN put spreads 60-90 days out against a core long if you need exposure to industrial semis; the implied message is that durability is unproven, so downside convexity is cheap relative to the stock’s recent run.
• Rotate a portion of analog exposure into under-owned industrial beneficiaries only on confirmation of Q2 order strength; if TXN’s next update shows continued broad-based demand, the second-order upside likely shows up first in automation and factory-electrification names over the following 1-3 months.